Designing specificity

How C4X Discovery identified its selective OX1R antagonist

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in a preclinical model of addiction.

The orexin system consists of two isoforms of orexin (hypocretin; HCRT) -- orexin-A and orexin-B -- that bind the G protein-coupled

Read the full 606 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers